SOURCE: Bioheart, Inc.

Bioheart, Inc.

March 17, 2014 08:18 ET

Bioheart Announces Joint Venture With Magnum Cell Therapies

SUNRISE, FL--(Marketwired - Mar 17, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases, announced today that it has entered into a joint venture with Magnum Cell Therapies (http://www.magnumterapiacelular.com/). 

Magnum Cell Therapies' mission is to provide the latest regenerative medicine therapies to patients suffering from degenerative diseases. Magnum's facilities include a state of the art clinic and laboratory located in Honduras. 

"We are thrilled to work with the team of specialists and scientists at Magnum. The facilities are top-notch and we are hopeful that Bioheart therapies can help many patients," said Kristin Comella, Bioheart's Chief Science Officer.

Bioheart will provide the necessary training and expertise to transfer Bioheart therapies to Magnum. Bioheart and Magnum will work closely with the Honduran Ministry of Health to make Bioheart protocols part of the standard of care for patients in Honduras and neighboring countries. Bioheart will assume 10% ownership of Magnum Cell Therapies. Magnum will offer these therapies to the more than 8 million people living in Honduras as well as being a premier site for medical tourism. 

About Bioheart, Inc.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. 

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient's quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart's leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. 

Contact Information

  • Media Contact:
    Carissa Matton
    Bioheart, Inc.
    13794 NW 4th Street, Suite 212
    Sunrise, Florida 33325
    Phone: 772.285.8511
    cmatton@bioheartinc.com